PT - JOURNAL ARTICLE AU - Cécile Delorme AU - Marion Houot AU - Charlotte Rosso AU - Stéphanie Carvalho AU - Thomas Nedelec AU - Redwan Maatoug AU - Victor Pitron AU - Salimata Gassama AU - Sara Sambin AU - Stéphanie Bombois AU - Bastien Herlin AU - Gaëlle Ouvrard AU - Gaëlle Bruneteau AU - Adèle Hesters AU - Ana Zenovia Gales AU - Bruno Millet AU - Foudil Lamari AU - Stéphane Lehericy AU - Vincent Navarro AU - Benjamin Rohaut AU - Sophie Demeret AU - Thierry Maisonobe AU - Marion Yger AU - Bertrand Degos AU - Louise-Laure Mariani AU - Christophe Bouche AU - Nathalie Dzierzynski AU - Bruno Oquendo AU - Flora Ketz AU - An-Hung Nguyen AU - Aurélie Kas AU - Jean-Yves Delattre AU - Jean-Christophe Corvol AU - on behalf of the CoCo-Neurosciences Study Group TI - The wide spectrum of neuropsychiatric complications in Covid-19 patients within a multidisciplinary hospital context AID - 10.1101/2020.10.21.20216747 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.21.20216747 4099 - http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216747.short 4100 - http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216747.full AB - Objective To describe the spectrum of neurological and psychiatric complications in patients with Covid-19 seen in a multidisciplinary center over six months.Methods We conducted a retrospective, observational study on all patients showing neurological or psychiatric symptoms in the context of Covid-19 seen in the Department of Neurology and Psychiatry of the APHP-Sorbonne University. We collected demographic data, medical and treatment history, comorbidities, symptoms, date of onset, and severity of Covid-19 infection, neurological and psychiatric symptoms, neurological and psychiatric examination data and, when available, results from cerebrospinal fluid (CSF) analysis, brain magnetic resonance (MRI) imaging, 18-fluorodesoxyglucose-position emission computed tomography (FDG-PET/CT)), electroencephalography (EEG) and electroneuromyography (ENMG).Results 245 patients were included in the analysis. One-hundred fourteen patients (47%) were admitted to the intensive care unit (ICU) and 10 (4%) died. The most frequently reported neuropsychiatric symptoms were motor deficit (41%), cognitive disturbance (35%), impaired consciousness (26%), psychiatric disturbance (24%), headache (20%) and behavioral disturbance (18%). The most frequent syndromes diagnosed were encephalopathy (43%), critical illness polyneuropathy and myopathy (26%), isolated psychiatric disturbance (18%), and cerebrovascular disorders (16%). No patients showed evidence of SARS-CoV-2 in their CSF. Encephalopathy was associated with greater age and higher risk of death. Critical illness neuromyopathy was associated with an extended stay in the ICU.Conclusions The majority of the neuropsychiatric complications recorded could be imputed to critical illness, intensive care and systemic inflammation, which contrasts with the paucity of more direct SARS-CoV-2-related complications or post-infection disorders.Competing Interest StatementCecile Delorme received a research grant from the FIA, travel funding from Merz Pharma, Boston Scientific and Medtronic. Vincent Navarro served as board member for UCB pharma, LivaNova, GW pharma et EISAI. Louise-Laure Mariani has received research support grants from INSERM, JNLF, The L Oreal Foundation; speech honoraria from CSL, Sanofi-Genzyme, Lundbeck, Teva; consultant for Alzprotect and received travel funding from the Movement Disorders Society, ANAINF, Merck, Merz, Medtronic, Teva and AbbVie, outside the submitted work. J.C. Corvol served on the scientific advisory boards for Biogen, UCB, Prevail Therapeutic, Idorsia, Ever Pharma, Denali, and has received grants from the Michael J Fox Foundation and Sanofi outside of this work. The other authors declare no potential financial conflict. Clinical TrialNCT04362930Funding StatementThe study received funding from the FIA (Federation Internationale de l Automobile.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with good clinical practice, the French regulation for retrospective studies on clinical data, and was compliant with the European General Data Protection Regulation (GDPR) and the French Commission Nationale de l Informatique et des Libertes (CNIL) rules. All patients (or their relatives in cases of impaired consciousness) received written information about the research, and consented to the use of their data. The study received the approval of the Sorbonne University Ethics Committee (N 2020 CER-202028). The study is registered on the clinicaltrials.gov website (NCT04362930). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data is available upon request to the corresponding author by request from any qualified investigator.